Literature DB >> 21241731

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

Troy J Kemp1, Allan Hildesheim, Mahboobeh Safaeian, Joseph G Dauner, Yuanji Pan, Carolina Porras, John T Schiller, Douglas R Lowy, Rolando Herrero, Ligia A Pinto.   

Abstract

Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix™ induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p<0.001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21241731      PMCID： PMC3046309          DOI： 10.1016/j.vaccine.2011.01.001

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  13 in total

1.  Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Authors:  Ligia A Pinto; Raphael Viscidi; Clayton D Harro; Troy J Kemp; Alfonso J García-Piñeres; Matthew Trivett; Franklin Demuth; Douglas R Lowy; John T Schiller; Jay A Berzofsky; Allan Hildesheim
Journal:  Virology       Date:  2006-07-24       Impact factor: 3.616

2.  Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Authors:  Troy J Kemp; Alfonso García-Piñeres; Roni T Falk; Sylviane Poncelet; Francis Dessy; Sandra L Giannini; Ana Cecilia Rodriguez; Carolina Porras; Rolando Herrero; Allan Hildesheim; Ligia A Pinto
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

3.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors:  Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

4.  Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.

Authors:  Marie-Pierre David; Koen Van Herck; Karin Hardt; Fabian Tibaldi; Gary Dubin; Dominique Descamps; Pierre Van Damme
Journal:  Gynecol Oncol       Date:  2009-02-12       Impact factor: 5.482

5.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

6.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Authors:  Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

7.  Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Allan Hildesheim; Ana C Rodríguez; Sholom Wacholder; Concepción Bratti; Diane Solomon; Paula González; Carolina Porras; Silvia Jiménez; Diego Guillen; Jorge Morales; Mario Alfaro; Jean Cyr; Kerrygrace Morrisey; Yenory Estrada; Bernal Cortés; Lidia Ana Morera; Enrique Freer; John Schussler; John Schiller; Douglas Lowy; Mark Schiffman
Journal:  Vaccine       Date:  2008-07-18       Impact factor: 3.641

8.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

10.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
View more
  62 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.

Authors:  Thomas J Hope
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

3.  Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Authors:  Sara L Bissett; Dianna Wilkinson; Kate I Tettmar; Nicky Jones; Elaine Stanford; Gitika Panicker; Helena Faust; Ray Borrow; Kate Soldan; Elizabeth R Unger; Joakim Dillner; Philip Minor; Simon Beddows
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

4.  Human papillomavirus-16/18 AS04-adjuvanted vaccine (cervarix®): a guide to its two-dose schedule in girls aged 9-14 years in the EU.

Authors:  Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

5.  Peptidic inhibitors for in vitro pentamer formation of human papillomavirus capsid protein l1.

Authors:  Ding-Yi Fu; Shi Jin; Dong-Dong Zheng; Xiao Zha; Yuqing Wu
Journal:  ACS Med Chem Lett       Date:  2015-02-25       Impact factor: 4.345

6.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Authors:  Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis
Journal:  Hum Vaccin Immunother       Date:  2012-11-13       Impact factor: 3.452

9.  Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens.

Authors:  Huizhun Zhao; Xiuyun Zhao; Peng Du; Gaofu Qi
Journal:  Tumour Biol       Date:  2016-07-23

10.  Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58.

Authors:  Martha J Brown; Hanna Seitz; Victoria Towne; Martin Müller; Adam C Finnefrock
Journal:  Clin Vaccine Immunol       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.